143 related articles for article (PubMed ID: 21472431)
21. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines.
Yoo BC; Ku JL; Hong SH; Shin YK; Park SY; Kim HK; Park JG
Int J Cancer; 2004 Feb; 108(4):532-9. PubMed ID: 14696117
[TBL] [Abstract][Full Text] [Related]
22. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
23. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
24. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
25. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
[TBL] [Abstract][Full Text] [Related]
26. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
27. Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling.
Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):692-703. PubMed ID: 29959879
[TBL] [Abstract][Full Text] [Related]
28. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Yamamoto K; Kikuchi Y; Kudoh K; Nagata I
J Cancer Res Clin Oncol; 2000 Mar; 126(3):168-72. PubMed ID: 10741911
[TBL] [Abstract][Full Text] [Related]
29. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
30. The Application of ATR-FTIR Spectroscopy and the Reversible DNA Conformation as a Sensor to Test the Effectiveness of Platinum(II) Anticancer Drugs.
Al-Jorani K; Rüther A; Martin M; Haputhanthri R; Deacon GB; Li HL; Wood BR
Sensors (Basel); 2018 Dec; 18(12):. PubMed ID: 30563229
[TBL] [Abstract][Full Text] [Related]
31. Cell discrimination by attenuated total reflection-Fourier transform infrared spectroscopy: the impact of preprocessing of spectra.
Gaigneaux A; Ruysschaert JM; Goormaghtigh E
Appl Spectrosc; 2006 Sep; 60(9):1022-8. PubMed ID: 17002828
[TBL] [Abstract][Full Text] [Related]
32. In situ research and diagnosis of breast cancer by using HOF-ATR-FTIR spectroscopy.
Lu Y; Zhao Y; Zhu Y; Xu X; Yin J
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Jul; 235():118178. PubMed ID: 32247254
[TBL] [Abstract][Full Text] [Related]
33. Increased γ-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin.
Adam-Zahir S; Plowman PN; Bourton EC; Sharif F; Parris CN
Chemotherapy; 2014; 60(5-6):310-20. PubMed ID: 26138778
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin Resistant Patterns in Ovarian Cell Line Using FTIR and Principle Component Analysis.
Zendehdel R; Masoudi-Nejad A; Mohammadzadeh J; H Shirazi F
Iran J Pharm Res; 2012; 11(1):235-40. PubMed ID: 24250445
[TBL] [Abstract][Full Text] [Related]
35. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
36. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
37. ATR-FTIR spectroscopy coupled with chemometric analysis discriminates normal, borderline and malignant ovarian tissue: classifying subtypes of human cancer.
Theophilou G; Lima KM; Martin-Hirsch PL; Stringfellow HF; Martin FL
Analyst; 2016 Jan; 141(2):585-94. PubMed ID: 26090781
[TBL] [Abstract][Full Text] [Related]
38. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
39. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
40. Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR-FTIR spectroscopy coupled with variable selection methods.
Lima KM; Gajjar KB; Martin-Hirsch PL; Martin FL
Biotechnol Prog; 2015; 31(3):832-9. PubMed ID: 25832726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
